Akimichi Morita

Nagoya, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 332 publications

Drug therapies and immune pathways in ocular manifestations of inflammatory skin diseases.

Drug therapies and immune pathways in ocular manifestations of inflammatory skin diseases.

Journal: Expert review of clinical immunology

Published: May 29, 2026

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: May 12, 2026

Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025).

Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025).

Journal: The Journal of dermatology

Published: April 30, 2026

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.

Journal: The Journal of dermatology

Published: April 28, 2026

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases.

Journal: Expert review of clinical immunology

Published: April 27, 2026

Topical Cycling and Systemic Eligibility in Patients With Psoriasis in Japan.

Topical Cycling and Systemic Eligibility in Patients With Psoriasis in Japan.

Journal: The Journal of dermatology

Published: March 31, 2026

Early Intervention Effects and Risk Factors for Residual Skin Changes in Infantile Hemangiomas.

Early Intervention Effects and Risk Factors for Residual Skin Changes in Infantile Hemangiomas.

Journal: The Journal of dermatology

Published: March 04, 2026

Early Initiation of UVB Phototherapy May Improve Outcomes in Alopecia Areata.

Early Initiation of UVB Phototherapy May Improve Outcomes in Alopecia Areata.

Journal: Photodermatology, photoimmunology & photomedicine

Published: February 23, 2026

Author Correction: GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region.

Author Correction: GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region.

Journal: Nature communications

Published: January 19, 2026

Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials.

Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials.

Journal: American journal of clinical dermatology

Published: January 15, 2026

Prevalence of melasma, quality-of-life impact and social stigmatization.

Prevalence of melasma, quality-of-life impact and social stigmatization.

Journal: Clinical and experimental dermatology

Published: January 05, 2026

Prevalence and impact of solar lentigines: An international survey.

Prevalence and impact of solar lentigines: An international survey.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 02, 2026

Showing 1-12 of 332

Last Updated: 09/26/2026